Richard A. Bond
Corporate Officer/Principal chez University of Houston
Profil
Richard A.
Bond is the founder of Inverseon, Inc. founded in 2004.
Currently, he is an Associate Professor at the University of Houston.
Previously, he worked as a Principal at Baylor University.
Dr. Bond received his graduate and doctorate degrees from the University of Houston.
Postes actifs de Richard A. Bond
| Sociétés | Poste | Début |
|---|---|---|
University of Houston
 University of Houston Other Consumer ServicesConsumer Services University of Houston System offers higher education degrees and job training or vocational study programs. It offers about 280 undergraduate and graduate degree programs in fields such as business, education, humanities and law. It was founded in 1927 and is headquartered in Houston, TX. | Corporate Officer/Principal | 13/04/2010 |
Anciens postes connus de Richard A. Bond
| Sociétés | Poste | Fin |
|---|---|---|
Inverseon, Inc.
 Inverseon, Inc. Pharmaceuticals: MajorHealth Technology Inverseon, Inc. is a private company developing a re-profiled beta blocker for the treatment of asthma and COPD. Inverseon’s scientific approach, “Paradoxical Pharmacology”, is based on observations that chronic effects of inverse agonist drugs are completely opposite to their acute effects. A similar paradigm shift occurred in the late 1990’s with the approval of the first beta blocker for congestive heart failure, a disease state where the drug was also originally contraindicated. Inverseon’s scientific founder, Professor Richard Bond, identified the mechanism of action as inverse agonism at the beta adrenergic receptor and hypothesized that this observation represented a general pharmacological phenomenon and identified asthma as another disease to target. To date, the company has achieved a number of important milestones: completing two open-label Phase 2a studies demonstrating a dose-response, a comment in The Lancet in 2009 highlighting the published human clinical trial, and 2009 issuance of their first U.S. patent. | Fondateur | 01/09/2012 |
| Baylor University | Corporate Officer/Principal | - |
Formation de Richard A. Bond
| University of Houston | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 1 |
|---|---|
Inverseon, Inc.
Inverseon, Inc. Pharmaceuticals: MajorHealth Technology Inverseon, Inc. is a private company developing a re-profiled beta blocker for the treatment of asthma and COPD. Inverseon’s scientific approach, “Paradoxical Pharmacology”, is based on observations that chronic effects of inverse agonist drugs are completely opposite to their acute effects. A similar paradigm shift occurred in the late 1990’s with the approval of the first beta blocker for congestive heart failure, a disease state where the drug was also originally contraindicated. Inverseon’s scientific founder, Professor Richard Bond, identified the mechanism of action as inverse agonism at the beta adrenergic receptor and hypothesized that this observation represented a general pharmacological phenomenon and identified asthma as another disease to target. To date, the company has achieved a number of important milestones: completing two open-label Phase 2a studies demonstrating a dose-response, a comment in The Lancet in 2009 highlighting the published human clinical trial, and 2009 issuance of their first U.S. patent. | Health Technology |
